FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Natera Inc NTRA
News
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Natera Reports Second Quarter 2026 Financial Results
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera to Report its Second Quarter Results on August 6, 2026
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
Natera Gets FDA Approval for Bladder-Cancer Test
United States